Logo image of RZLT

REZOLUTE INC (RZLT) Stock Price, Quote, News and Overview

NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD

4.53  -0.1 (-2.16%)

After market: 4.4803 -0.05 (-1.1%)

RZLT Quote, Performance and Key Statistics

REZOLUTE INC

NASDAQ:RZLT (2/21/2025, 8:00:01 PM)

After market: 4.4803 -0.05 (-1.1%)

4.53

-0.1 (-2.16%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.19
52 Week Low1.57
Market Cap262.47M
Shares57.94M
Float52.80M
Yearly Dividend0
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/amc
IPO12-23 2011-12-23


RZLT short term performance overview.The bars show the price performance of RZLT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10

RZLT long term performance overview.The bars show the price performance of RZLT in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of RZLT is 4.53 USD. In the past month the price decreased by -9.22%. In the past year, price increased by 163.37%.

REZOLUTE INC / RZLT Daily stock chart

RZLT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About RZLT

Company Profile

RZLT logo image Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 59 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

Company Info

REZOLUTE INC

275 Shoreline Drive, Suite 500

Redwood City CALIFORNIA 94065 US

CEO: Nevan Elam

Employees: 59

Company Website: https://www.rezolutebio.com/

Investor Relations: http://ir.rezolutebio.com

Phone: 16502064507

REZOLUTE INC / RZLT FAQ

What is the stock price of REZOLUTE INC today?

The current stock price of RZLT is 4.53 USD. The price decreased by -2.16% in the last trading session.


What is the ticker symbol for REZOLUTE INC stock?

The exchange symbol of REZOLUTE INC is RZLT and it is listed on the Nasdaq exchange.


On which exchange is RZLT stock listed?

RZLT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for REZOLUTE INC stock?

16 analysts have analysed RZLT and the average price target is 13.37 USD. This implies a price increase of 195.22% is expected in the next year compared to the current price of 4.53. Check the REZOLUTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REZOLUTE INC worth?

REZOLUTE INC (RZLT) has a market capitalization of 262.47M USD. This makes RZLT a Micro Cap stock.


How many employees does REZOLUTE INC have?

REZOLUTE INC (RZLT) currently has 59 employees.


What are the support and resistance levels for REZOLUTE INC (RZLT) stock?

REZOLUTE INC (RZLT) has a support level at 4.51 and a resistance level at 4.84. Check the full technical report for a detailed analysis of RZLT support and resistance levels.


Should I buy REZOLUTE INC (RZLT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REZOLUTE INC (RZLT) stock pay dividends?

RZLT does not pay a dividend.


When does REZOLUTE INC (RZLT) report earnings?

REZOLUTE INC (RZLT) will report earnings on 2025-05-13, after the market close.


What is the Price/Earnings (PE) ratio of REZOLUTE INC (RZLT)?

REZOLUTE INC (RZLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).


What is the Short Interest ratio of REZOLUTE INC (RZLT) stock?

The outstanding short interest for REZOLUTE INC (RZLT) is 3.07% of its float. Check the ownership tab for more information on the RZLT short interest.


RZLT Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to RZLT. When comparing the yearly performance of all stocks, RZLT is one of the better performing stocks in the market, outperforming 96.43% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RZLT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RZLT. RZLT has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RZLT Financial Highlights

Over the last trailing twelve months RZLT reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -10.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.51%
ROE -71.43%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%18.52%
Sales Q2Q%N/A
EPS 1Y (TTM)-10.91%
Revenue 1Y (TTM)N/A

RZLT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to RZLT. The Buy consensus is the average rating of analysts ratings from 16 analysts.


Ownership
Inst Owners74.05%
Ins Owners0.86%
Short Float %3.07%
Short Ratio3.39
Analysts
Analysts86.25
Price Target13.37 (195.14%)
EPS Next Y-21.95%
Revenue Next YearN/A